Bis-indols

A novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells

Claudio Pisano, Peter Kollar, Maurizio Gianní, Yesim Kalac, Vincenzo Giordano, Fabiana Fosca Ferrara, Richard Tancredi, Antonio Devoto, Alessandra Rinaldi, Alessandro Rambaldi, Sergio Penco, Mauro Marzi, Giampiero Moretti, Loredana Vesci, Ornella Tinti, Paolo Carminati, Mineko Terao, Enrico Garattini

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Enhancing the pharmacologic activity of all-trans retinoic acid (ATRA) is potentially useful in the management of acute promyelocytic leukemia (APL) and other types of myeloid leukemia. In this report, we identify a novel class of experimental agents selectively potentiating the cytodifferentiating activity of ATRA and synthetic retinoic acid receptor α agonists in APL and other myeloid leukemia cell lines. These agents have a bis-indolic structure (BISINDS), and ST1346 is the prototypical compound of the series. Gene-profiling experiments and determination of the level of expression of myeloid-associated markers indicate that ST1346 stimulates many aspects of the granulocytic maturation process set in motion by ATRA. Stimulation of the cytodifferentiating activity of ATRA by ST1346 enhances the efficacy of the retinoid in vivo, as demonstrated in the APL model of the severe combined immunodeficiency (SCID) mouse receiving transplants of NB4 cells. Although the molecular mechanisms underlying the ATRA-potentiating action of ST1346 and congeners have not been completely clarified, bis-indols are not ligands and do not exert any direct effect on the ATRA-dependent transactivation of nuclear receptors. However, ST1346 inhibits the down-regulation of cyclic adenosine monophosphate (cAMP)-dependent CREBtranscriptional complexes and enhances the level of expression of signal transducers and activators of transcription-1 (STAT1), 2 putative molecular determinants of the differentiation process activated by ATRA in APL cells. More importantly, ST1346 relieves the down-regulation of Jun N-terminal kinases (JNK) afforded by ATRA. In addition, a specific JNK inhibitor blocks the enhancing effect of ST1346 on ATRA-induced maturation of NB4 cells. This demonstrates an important role for the mitogen-activated protein kinase in the molecular mechanisms underlying the pharmacologic activity of the bis-indol.

Original languageEnglish
Pages (from-to)3719-3730
Number of pages12
JournalBlood
Volume100
Issue number10
DOIs
Publication statusPublished - Nov 15 2002

Fingerprint

Myeloid Leukemia
Retinoids
Myeloid Cells
Tretinoin
Molecules
Acute Promyelocytic Leukemia
STAT2 Transcription Factor
Phosphotransferases
Down-Regulation
STAT1 Transcription Factor
Severe Combined Immunodeficiency
Transplants
Retinoic Acid Receptors
Cytoplasmic and Nuclear Receptors
ST 1346
Mitogen-Activated Protein Kinases
Cyclic AMP
Transcriptional Activation
Genes
Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Bis-indols : A novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. / Pisano, Claudio; Kollar, Peter; Gianní, Maurizio; Kalac, Yesim; Giordano, Vincenzo; Ferrara, Fabiana Fosca; Tancredi, Richard; Devoto, Antonio; Rinaldi, Alessandra; Rambaldi, Alessandro; Penco, Sergio; Marzi, Mauro; Moretti, Giampiero; Vesci, Loredana; Tinti, Ornella; Carminati, Paolo; Terao, Mineko; Garattini, Enrico.

In: Blood, Vol. 100, No. 10, 15.11.2002, p. 3719-3730.

Research output: Contribution to journalArticle

Pisano, C, Kollar, P, Gianní, M, Kalac, Y, Giordano, V, Ferrara, FF, Tancredi, R, Devoto, A, Rinaldi, A, Rambaldi, A, Penco, S, Marzi, M, Moretti, G, Vesci, L, Tinti, O, Carminati, P, Terao, M & Garattini, E 2002, 'Bis-indols: A novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells', Blood, vol. 100, no. 10, pp. 3719-3730. https://doi.org/10.1182/blood-2002-03-0720
Pisano, Claudio ; Kollar, Peter ; Gianní, Maurizio ; Kalac, Yesim ; Giordano, Vincenzo ; Ferrara, Fabiana Fosca ; Tancredi, Richard ; Devoto, Antonio ; Rinaldi, Alessandra ; Rambaldi, Alessandro ; Penco, Sergio ; Marzi, Mauro ; Moretti, Giampiero ; Vesci, Loredana ; Tinti, Ornella ; Carminati, Paolo ; Terao, Mineko ; Garattini, Enrico. / Bis-indols : A novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. In: Blood. 2002 ; Vol. 100, No. 10. pp. 3719-3730.
@article{ed199d4a2fae464db91efb99000bb7a2,
title = "Bis-indols: A novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells",
abstract = "Enhancing the pharmacologic activity of all-trans retinoic acid (ATRA) is potentially useful in the management of acute promyelocytic leukemia (APL) and other types of myeloid leukemia. In this report, we identify a novel class of experimental agents selectively potentiating the cytodifferentiating activity of ATRA and synthetic retinoic acid receptor α agonists in APL and other myeloid leukemia cell lines. These agents have a bis-indolic structure (BISINDS), and ST1346 is the prototypical compound of the series. Gene-profiling experiments and determination of the level of expression of myeloid-associated markers indicate that ST1346 stimulates many aspects of the granulocytic maturation process set in motion by ATRA. Stimulation of the cytodifferentiating activity of ATRA by ST1346 enhances the efficacy of the retinoid in vivo, as demonstrated in the APL model of the severe combined immunodeficiency (SCID) mouse receiving transplants of NB4 cells. Although the molecular mechanisms underlying the ATRA-potentiating action of ST1346 and congeners have not been completely clarified, bis-indols are not ligands and do not exert any direct effect on the ATRA-dependent transactivation of nuclear receptors. However, ST1346 inhibits the down-regulation of cyclic adenosine monophosphate (cAMP)-dependent CREBtranscriptional complexes and enhances the level of expression of signal transducers and activators of transcription-1 (STAT1), 2 putative molecular determinants of the differentiation process activated by ATRA in APL cells. More importantly, ST1346 relieves the down-regulation of Jun N-terminal kinases (JNK) afforded by ATRA. In addition, a specific JNK inhibitor blocks the enhancing effect of ST1346 on ATRA-induced maturation of NB4 cells. This demonstrates an important role for the mitogen-activated protein kinase in the molecular mechanisms underlying the pharmacologic activity of the bis-indol.",
author = "Claudio Pisano and Peter Kollar and Maurizio Giann{\'i} and Yesim Kalac and Vincenzo Giordano and Ferrara, {Fabiana Fosca} and Richard Tancredi and Antonio Devoto and Alessandra Rinaldi and Alessandro Rambaldi and Sergio Penco and Mauro Marzi and Giampiero Moretti and Loredana Vesci and Ornella Tinti and Paolo Carminati and Mineko Terao and Enrico Garattini",
year = "2002",
month = "11",
day = "15",
doi = "10.1182/blood-2002-03-0720",
language = "English",
volume = "100",
pages = "3719--3730",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Bis-indols

T2 - A novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells

AU - Pisano, Claudio

AU - Kollar, Peter

AU - Gianní, Maurizio

AU - Kalac, Yesim

AU - Giordano, Vincenzo

AU - Ferrara, Fabiana Fosca

AU - Tancredi, Richard

AU - Devoto, Antonio

AU - Rinaldi, Alessandra

AU - Rambaldi, Alessandro

AU - Penco, Sergio

AU - Marzi, Mauro

AU - Moretti, Giampiero

AU - Vesci, Loredana

AU - Tinti, Ornella

AU - Carminati, Paolo

AU - Terao, Mineko

AU - Garattini, Enrico

PY - 2002/11/15

Y1 - 2002/11/15

N2 - Enhancing the pharmacologic activity of all-trans retinoic acid (ATRA) is potentially useful in the management of acute promyelocytic leukemia (APL) and other types of myeloid leukemia. In this report, we identify a novel class of experimental agents selectively potentiating the cytodifferentiating activity of ATRA and synthetic retinoic acid receptor α agonists in APL and other myeloid leukemia cell lines. These agents have a bis-indolic structure (BISINDS), and ST1346 is the prototypical compound of the series. Gene-profiling experiments and determination of the level of expression of myeloid-associated markers indicate that ST1346 stimulates many aspects of the granulocytic maturation process set in motion by ATRA. Stimulation of the cytodifferentiating activity of ATRA by ST1346 enhances the efficacy of the retinoid in vivo, as demonstrated in the APL model of the severe combined immunodeficiency (SCID) mouse receiving transplants of NB4 cells. Although the molecular mechanisms underlying the ATRA-potentiating action of ST1346 and congeners have not been completely clarified, bis-indols are not ligands and do not exert any direct effect on the ATRA-dependent transactivation of nuclear receptors. However, ST1346 inhibits the down-regulation of cyclic adenosine monophosphate (cAMP)-dependent CREBtranscriptional complexes and enhances the level of expression of signal transducers and activators of transcription-1 (STAT1), 2 putative molecular determinants of the differentiation process activated by ATRA in APL cells. More importantly, ST1346 relieves the down-regulation of Jun N-terminal kinases (JNK) afforded by ATRA. In addition, a specific JNK inhibitor blocks the enhancing effect of ST1346 on ATRA-induced maturation of NB4 cells. This demonstrates an important role for the mitogen-activated protein kinase in the molecular mechanisms underlying the pharmacologic activity of the bis-indol.

AB - Enhancing the pharmacologic activity of all-trans retinoic acid (ATRA) is potentially useful in the management of acute promyelocytic leukemia (APL) and other types of myeloid leukemia. In this report, we identify a novel class of experimental agents selectively potentiating the cytodifferentiating activity of ATRA and synthetic retinoic acid receptor α agonists in APL and other myeloid leukemia cell lines. These agents have a bis-indolic structure (BISINDS), and ST1346 is the prototypical compound of the series. Gene-profiling experiments and determination of the level of expression of myeloid-associated markers indicate that ST1346 stimulates many aspects of the granulocytic maturation process set in motion by ATRA. Stimulation of the cytodifferentiating activity of ATRA by ST1346 enhances the efficacy of the retinoid in vivo, as demonstrated in the APL model of the severe combined immunodeficiency (SCID) mouse receiving transplants of NB4 cells. Although the molecular mechanisms underlying the ATRA-potentiating action of ST1346 and congeners have not been completely clarified, bis-indols are not ligands and do not exert any direct effect on the ATRA-dependent transactivation of nuclear receptors. However, ST1346 inhibits the down-regulation of cyclic adenosine monophosphate (cAMP)-dependent CREBtranscriptional complexes and enhances the level of expression of signal transducers and activators of transcription-1 (STAT1), 2 putative molecular determinants of the differentiation process activated by ATRA in APL cells. More importantly, ST1346 relieves the down-regulation of Jun N-terminal kinases (JNK) afforded by ATRA. In addition, a specific JNK inhibitor blocks the enhancing effect of ST1346 on ATRA-induced maturation of NB4 cells. This demonstrates an important role for the mitogen-activated protein kinase in the molecular mechanisms underlying the pharmacologic activity of the bis-indol.

UR - http://www.scopus.com/inward/record.url?scp=0037111549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037111549&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-03-0720

DO - 10.1182/blood-2002-03-0720

M3 - Article

VL - 100

SP - 3719

EP - 3730

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -